Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094004 | 0.86 | DRD2 (0.51) | DRD2SLC6A3SLC6A2ALDH1A1CYP2D6 | |
| SCHEMBL19974180 | 0.84 | SLC6A4 (0.59) | DRD2SLC6A3SLC6A2CYP2D6DCPS | |
| SCHEMBL2095321 | 0.84 | SLC6A3 (0.49) | DRD2SLC6A3SLC6A2CYP2D6EPHX2 | |
| SCHEMBL6941780 | 0.82 | DCPS (0.53) | DRD2SLC6A3SLC6A2CYP2D6EPHX2 | |
| SCHEMBL8109175 | 0.82 | DCPS (0.53) | DRD2SLC6A3SLC6A2CYP2D6EPHX2 | |
| SCHEMBL1427490 | 0.79 | KDM4E (0.59) | DRD2SLC6A3ALDH1A1MEN1KMT2A | |
| SCHEMBL31538649 | 0.79 | CYP3A4 (0.53) | DRD2SLC6A3SLC6A2ALDH1A1MEN1 | |
| SCHEMBL3161038 | 0.78 | MEN1 (0.82) | DRD2ALDH1A1CYP2D6MEN1KMT2A | |
| SCHEMBL10470571 | 0.78 | MEN1 (0.59) | DRD2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5543227 | 0.78 | DRD4 (0.55) | DRD2ALDH1A1KMT2AEPHX2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| EP-3452464-B1 | PYRAZOLE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USE THEREOF | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | IKZF1, IKZF2, IKZF3 | DRD2 3504/4885SLC6A3 4547/4885SLC6A2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.